SMS Lifesciences India Ltd

Haleos Labs Ltd is communicating with its physical shareholders, providing them with a web-link and QR code to access the Annual Report for 2025-26 and the AGM Notice. This follows a previous reminder for shareholders to update their KYC details. The company reiterates its request for shareholders in demat form to update their email IDs with Depository Participants and those in physical form to contact the Registrar and Transfer Agent (RTA). The 20th AGM is scheduled for September 30, 2026, via video conference. Key dates for dividend record and e-voting have also been provided.

Haleos Labs Ltd (formerly SMS Lifesciences India Limited) has issued a notice for its 20th Annual General Meeting (AGM) to be held on Wednesday, September 30, 2026, at 3:00 p.m. via Video Conference. The agenda includes the adoption of audited standalone and consolidated financial statements for the fiscal year ended March 31, 2026, the declaration of a dividend of ₹1.50 per equity share (15%), the re-appointment of Mr. TVVSN Murthy as a director, and the appointment of M/s. Suryanarayana & Suresh as statutory auditors for a five-year term. The notice and e-voting details will be available on the company's and CDSL's websites.

Haleos Labs Ltd has submitted its Annual Report for the fiscal year ended March 31, 2026. The report includes the Notice for the 20th Annual General Meeting (AGM), scheduled for September 30, 2026, to be held via Video Conferencing. The company has dispatched the Annual Report and AGM Notice electronically to shareholders whose email addresses were registered by September 4, 2026, in line with the 'Green Initiative' by the Ministry of Corporate Affairs and SEBI. Physical copies will be sent to shareholders who have not registered their email addresses. The report covers financial statements, corporate governance, and management discussions.

Haleos Labs Ltd has announced that Wednesday, September 23, 2026, has been fixed as the record date for determining shareholder entitlement for the dividend for the year 2025-26 and for casting votes at the 20th Annual General Meeting (AGM). The AGM is scheduled for Wednesday, September 30, 2026. The company also reiterated its policy to pay dividends electronically, discontinuing physical payment methods like dividend warrants, in compliance with SEBI regulations. Shareholders are urged to update their bank account details to ensure timely dividend credit.

Haleos Labs Ltd has announced the schedule for its 20th Annual General Meeting (AGM), which will be held on Wednesday, September 30, 2026, via Video Conferencing/OAVM. This follows up on their communication dated August 5, 2026. The company has also detailed an events calendar leading up to the AGM, including cut-off dates for notice dispatch, AGM voting, dividend entitlement, speaker registration, and TDS declarations. Central Depository Services (India) Ltd has been appointed as the authorized agency for e-voting facilities, and Mr. C. Sudhir Babu will serve as the Scrutinizer for the e-voting process. The provisions of Book Closure are omitted as per SEBI regulations.

Haleos Labs Ltd has announced its Board of Directors has recommended a dividend of ₹1.50 per equity share (15%) for the financial year ended March 31, 2026. This dividend is subject to shareholder approval at the upcoming 20th AGM. The company also informed shareholders about the tax implications, including Tax Deducted at Source (TDS), as per the Income Tax Act 2025. Shareholders are required to submit necessary declarations and update their PAN, address, and residential status by September 25, 2026, to ensure correct withholding tax application. Communications will primarily be via registered email, and shareholders are urged to register their email IDs.

Haleos Labs Ltd's material subsidiary, Mahi Drugs Private Limited, has appointed Annapragada & Co. as its Cost Auditors for the financial year 2026-27. Additionally, Mr. Vincent P. Asaro has been appointed as a Nominee Director, effective August 5, 2026, nominated by ChemWerth Inc. He replaces Mr. M. Madhu Rao. Mr. Asaro brings extensive experience in finance and pharmaceutical operations, currently serving as President of ChemWerth Inc. The appointments were approved at a Board meeting of the subsidiary held on August 5, 2026.

Haleos Labs Ltd announced the reappointment of Dr. Mannam Malakondaiah and Dr. Srinivas Samavedam as Independent Directors for a second consecutive term of 5 years, effective November 13, 2026. This decision, approved by the Board of Directors based on the Nomination and Remuneration Committee's recommendation, is subject to shareholder approval. Dr. Malakondaiah, a retired IPS officer, brings extensive administrative and leadership experience. Dr. Samavedam is a renowned Critical Care Medicine specialist with over 26 years of experience. Both directors have been serving the company since November 13, 2021.

Haleos Labs Ltd announced the outcome of its 98th Board meeting held on August 5, 2026. The Board approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. Additionally, the re-appointment of two Independent Directors for a second term, subject to shareholder approval, was approved. The Board also approved the revision of managerial remuneration for the Managing Director and the Board's Report for the year ended March 31, 2026. The 20th Annual General Meeting is scheduled for September 30, 2026, to be held via VC/OAVM.

Haleos Labs Ltd has scheduled a Board of Directors meeting for August 5, 2026. The primary agenda is to consider and approve the unaudited financial results for the quarter ended June 30, 2026, on both standalone and consolidated bases. Additionally, the board will review the Board report for the fiscal year 2025-26 and determine the date for the 20th Annual General Meeting. The trading window for designated persons and their immediate relatives will remain closed until August 8, 2026, in compliance with SEBI regulations.